Skip to main content

Volume 13 Supplement 1

The evolution of anti-TNF therapy in rheumatic disease: experience, insights and advances


Edited by Joachim Kalden

Publication of this supplement is sponsored by Merck & Company, Inc, Whitehouse Station, New Jersey, USA.

  1. Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Contro...

    Authors: Josef S Smolen and Paul Emery
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S2
  2. Treatment strategies for rheumatoid arthritis (RA) will continue to evolve as new drugs are developed, as new data become available, and as our potential to achieve greater and more consistent outcomes becomes...

    Authors: Ferdinand C Breedveld and Bernard Combe
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S3
  3. Structural changes of bone and cartilage are a hallmark of inflammatory joint diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Despite certain similaritie...

    Authors: Georg Schett, Laura C Coates, Zoe R Ash, Stefanie Finzel and Phillip G Conaghan
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S4
  4. Treatment of inflammatory arthritides - including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis - has seen much progress in recent years, partially due to increased understanding of the...

    Authors: Paul P Tak and Joachim R Kalden
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S5

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage 
    1,885 Altmetric mentions